Figure S11 from SIRT2 Regulates the SMARCB1 Loss-Driven Differentiation Block in ATRT

Le résumé fourni par la source

SIRT2 inhibition suppressed BT16(MYC) ATRT growth in vivo. A. Bioluminescence images of orthotopic ATRT tumors treated with Vehicle (Control) or TM. B. Survival analysis of Vehicle vs TM treated animals (median 19 days vs 33 days, log rank test p<0.05, n=4). C. Immunohistochemical (IHC) stains of cerebellar tumors from BT16(MYC) injected mice are shown (40x magnification). FOXM1 accumulation in mice tumors 4 weeks TM treatment. D. Quantification of Image C. Plots show values from quantification of representative images.TM treatment decreased oncogenic marker FOXM1 (p<0.05). E. Ki67 accumulation in mice tumors 4 weeks TM treatment (40x). F. Quantification of Image E. Plots show values from quantification representative images. Stain accumulation from 5 fields of each slide were analyzed using ImageJ program.TM treatment decreased oncogenic marker KI67 (* p<0.05). G. MEF2A accumulation in mice tumors 4 weeks TM treatment (40x). H. Quantification of Image G (40x magnification). Plots show values from quantification representative images. Stain accumulation from 5 fields of each slide were analyzed using ImageJ program. TM treatment increased accumulation neuronal differentiation marker MEF2A (p<0.05).

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.